Shanghai Pharmaceuticals Holding Co., Ltd (HKG:2607)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
12.72
+0.02 (0.16%)
Jul 28, 2025, 4:09 PM HKT
0.16%
Market Cap69.70B
Revenue (ttm)295.77B
Net Income (ttm)4.66B
Shares Outn/a
EPS (ttm)1.25
PE Ratio14.97
Forward PE13.53
Dividend0.32 (2.50%)
Ex-Dividend DateJul 16, 2025
Volume3,330,557
Average Volume4,643,057
Open12.80
Previous Close12.70
Day's Range12.62 - 12.84
52-Week Range10.04 - 14.70
Beta0.43
RSI69.43
Earnings DateAug 29, 2025

About HKG:2607

Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric and neurological, tumor, cardiovascular, digestive metabolism, psychoneurotic, neoplasm, respiratory system, and anti-infection diseases, as well as in... [Read more]

Sector Healthcare
Founded 1994
Employees 49,402
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2607
Full Company Profile

Financial Performance

In 2024, HKG:2607's revenue was 275.25 billion, an increase of 5.75% compared to the previous year's 260.30 billion. Earnings were 4.55 billion, an increase of 20.82%.

Financial numbers in CNY Financial Statements

News

Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million

On Wednesday, Hutchmed (China) Limited (NASDAQ: HCM) entered into two agreements to divest its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for approximately $608 million ...

7 months ago - Benzinga